Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Extra Corpor Technol ; 44(2): 66-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22893985

ABSTRACT

Angiotensin converting enzyme inhibitors (ACEIs) are widely used in the treatment of hypertension, myocardial infarction, and congestive heart failure. They have a known adverse effect of unresponsiveness to vasoconstrictors resulting in hypotension for the patients undergoing cardiac surgery. We report a case of a 43-year-old female patient with preoperative lisinopril (2.5 mg per day for a week prior to cardiac surgery), who was diagnosed with severe mitral and tricuspid valve regurgitation. She underwent both a mitral and tricuspid valve replacement operation using cardiopulmonary bypass (CPB). To address her ACEI-associated hypotension on cardiopulmonary bypass, bypass flows were as high as cardiac index of greater than 3 (3.1 +/- .2) L/min/m2 to provide sufficient perfusion indicated by cerebral oxymetry monitoring and adequate urine on pump. In addition, due to unresponsiveness to regular concentration of neosynephrine (neo), boluses of higher concentrations up to 320 microg/mL of neo were administered to maintain the perfusion pressure on pump. The patient was weaned from CPB uneventfully and was discharged home on postoperative day 7. Additional therapeutic treatment to ACEI-associated hypotension and unresponsiveness to neo for the patients undergoing cardiac surgery using CPB is reviewed as well in this paper.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/adverse effects , Cardiopulmonary Bypass , Lisinopril/adverse effects , Phenylephrine/administration & dosage , Vasoconstrictor Agents/administration & dosage , Adult , Female , Humans , Hypotension/chemically induced , Mitral Valve Insufficiency/surgery , Tricuspid Valve Insufficiency/surgery
2.
Heart Surg Forum ; 7(3): E189-90, 2004.
Article in English | MEDLINE | ID: mdl-15262599

ABSTRACT

Nesiritide is primarily used in the treatment of acutely decompensated chronic heart failure. It may also be useful in the postoperative management of patients with an exacerbation of heart failure after cardiac surgery. The management of a patient with cardiogenic shock after acute papillary muscle rupture is described. The patient exhibited signs of postoperative heart failure, and nesiritide therapy was instituted to lower filling pressures and achieve diuresis. This drug may be useful when patients with heart failure undergo cardiac surgery and continue to show evidence of heart failure in the postoperative period.


Subject(s)
Heart Failure/etiology , Heart Failure/prevention & control , Heart Valve Prosthesis/adverse effects , Mitral Valve Insufficiency/surgery , Natriuretic Peptide, Brain/therapeutic use , Adult , Cardiotonic Agents/therapeutic use , Humans , Male , Postoperative Care/methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...